Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Explore how proteomics enhances infectious disease detection, pathogen identification, and host response profiling in ...

Chinese researchers have used a 78-qubit superconducting quantum processor to demonstrate that structured random pulses can hold off the chaotic heating that rapidly destroys quantum information. In ...

Tucked away in southern Oregon lies a city where your Social Security check might actually cover your living expenses without requiring creative accounting or a side hustle selling handcrafted items ...

Kingdom Come State Park, perched atop one of Kentucky’s highest mountains, offers yet another perspective on the region’s natural beauty. The park features old-growth forest that escaped logging, ...

Europe has strengthened its push for technological sovereignty with the launch of the Euro Q Exa quantum computing system in Munich, marking a significant addition to the continent’s developing ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Travel and Tour World (TTW) has unveiled its new research, "50 heritage sites in the world for 2026," highlighting the landmarks shaping the future of heritage tourism. Based on editorial research, ...

Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...

Bernard Jackman believes IRFU high-performance director David Humphreys has a major job on his hands to address the player pathway system in the country that has failed to widen the playing pool.

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...